Nasal commensal *Staphylococcus epidermidis* enhances interferon-λ-dependent immunity against influenza virus

Hyun Jik Kim¹², Ara Jo¹, Yung Jin Jeon⁵, Sujin An¹, Kang-Mu Lee³, Sang Sun Yoon⁴† and Jae Young Choi⁴†

Abstract

Background: *Staphylococcus epidermidis* is one of the most abundant colonizers of healthy human mucosa including that in the respiratory tract. As the respiratory microbiome has been linked to host immune responses, this study sought to determine the role of nasal mucosa-associated *S. epidermidis* in innate immune responses against the influenza A virus (IAV). *S. epidermidis* strains were isolated from nasal mucus samples of healthy individuals. The effects of these mucosa-derived commensal strains on interferon (IFN)-dependent innate immunity and IAV infection dynamics were tested in vitro using normal human nasal epithelial (NHNE) cells and human turbinate mucosa. The effects of *S. epidermidis* on antiviral immunity were also tested in vivo using an acute IAV infection mouse model.

Results: Exposure of NHNE cells to nasal mucosa-derived *S. epidermidis* increased IFN-λ mRNA and secreted protein levels in the absence of viral stimulation. In the context of IAV infection, NHNE exposure to *S. epidermidis* prevented an increase in the viral burden, as revealed by IAV PA mRNA abundance, IAV nucleoprotein levels, and viral titers. *S. epidermidis* also enhanced transcription of IFN-stimulated genes independently of Toll-like receptor 2 and further induced IFN-λ production in IAV-infected cells by promoting phosphorylation of interferon regulatory factor 7. In a murine infection model, *S. epidermidis* prevented the spread of IAV to the lungs by stimulating IFN-λ innate immunity and suppressing IAV replication in the nasal mucosa.

Conclusion: The human nasal commensal *S. epidermidis* mediates front-line antiviral protection against IAV infection through modulation of IFN-λ-dependent innate immune mechanisms in the nasal mucosa, thereby demonstrating the role of host-bacterial commensalism in shaping human antiviral responses.

Keywords: Influenza A virus, Microbiome, Nasal commensal, Innate immunity, Interferon

Background

The innate immune system of the respiratory epithelium serves as the first line of defense against respiratory viruses, including the influenza A virus (IAV), by producing interferon (IFN), a key molecule in the antiviral response [1]. IFNs including IFN-α, -β, -γ, and -λ enable substantial heterogeneity in host responses to respiratory viral infections, with specific IFNs interacting with different viruses to influence antiviral innate immune responses in the respiratory epithelium [1, 2]. Emerging evidence has indicated that among the IFN family of cytokines IFN-λ is a critical immune modulator against viral infection in the epithelial mucosa and the need for rapid immune responses to the respiratory virus is acquired by the activation of IFN-λ [3–7]. IFN-λ is believed to be primarily responsible for protection against viral invaders in the respiratory tract and to play an important role in local antiviral innate immunity [3, 5]. However, understanding of the modulators involved in

---

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
IFN-λ production, especially within the context of in vivo respiratory viral infections, remains limited. Human mucosal surfaces are in direct contact with the external environment and are, therefore, susceptible to invasion and colonization by various pathogens [8]. Studies on the clear reaction of the mucosal microbiome with the host increasingly take into consideration the contribution of mucosal immune responses and specific microbiome-mediated protection against infection from external pathogens to integrate environmental signals [9]. Respiratory mucosa, including that of nasal passages, is constantly exposed to inhaled pathogens, which directly impact the mucosal immune mechanisms [9, 10]. Inhaled pathogens encounter the host immune system for the first time in respiratory mucosa; especially, the nasal passage and microbial characteristics of the nasal mucus directly impact the mechanisms of initial immune responses [11–14]. Thus, insights into the microbiota of the human nasal mucus can provide fundamental information regarding susceptibility to respiratory viral infections and factors contributing to related immune mechanisms, such as induction of IFNs [15, 16]. However, our knowledge of microbial composition in healthy nasal mucus is limited and the responses to inhaled pathogens or reasons for their colonization have not been comprehensively examined.

Based on increasing evidence of microbiome-regulated host immune homeostasis [11–13, 15], we assessed the microbial composition in healthy nasal mucus and subsequently investigated whether nasal commensal contributes to antiviral defense mechanisms in human nasal mucosa as a signaling modulator of antiviral immunity against IAV infection. The present study identified Staphylococcus epidermidis as its most abundant constituent and showed that S. epidermidis which were isolated from healthy human nasal mucus accelerated the clearance of IAV from nasal epithelium through IFN-λ-related immune responses. Furthermore, human nasal commensal S. epidermidis prevents IAV lung infection in mice by enhancing IFN-λ-related innate immune responses in the nasal mucosa. Overall, we present evidence of a key mechanistic link between the susceptibility to viral infections and nasal microbiome-mediated innate immunity.

Methods
Additional methodological details are available in Additional file 1.

Participant recruitment
Information on the 37 healthy subjects enrolled in this study and the exclusion criteria are described in Additional file 1. Participation was voluntary, with written informed consent obtained from all subjects. The Institutional Review Board of the Seoul National University College of Medicine approved the protocol for this study (IRB #C2012248 [943]).

Sample collection
Mucus and/or nasal mucosa from the middle turbinates of the human subjects were collected and assessed for quality as described in Additional file 2: Movie S1).

Nasal mucus microbiome characterization
For bacterial colony isolation, the mucus was placed in lysogeny broth (LB) plates. After 2 days incubation, bacterial colonies were obtained from the LB plates (Additional file 1: Figure S2) and the species of each colony were identified using GS-FLX 454 pyrosequencing by 16S rRNA gene amplification. S. epidermidis strains (N1-N4) from four individuals were used in the study (Additional file 1: Figure S2).

Viruses and reagents
Influenza A virus strain A/Wilson-Smith/1933 H1N1 (IAV A/WS/33; ATCC, Manassas, VA, USA) was used in this study. Viruses were cultured and titrated using Madin-Darby canine kidney (MDCK) cells according to standard procedures [14].

Cell culture and infection
Normal human nasal epithelial (NHNE) cells from five subjects were cultured using an air-liquid interface method [17]. Cells were used 14 days following the creation of the air-liquid interface. S. epidermidis and/or IAV infections are described in Additional file 1.

Real-time PCR
Levels of transcripts encoding IFN-α, IFN-β, IFN-λ1, IFN-λ2/3, and IFN-γ, or IAV PA were determined using real-time PCR as described in Additional file 1.

Quantification of secreted IFN-λ
Secreted human IFN-λ and mouse IFN-λ2/3 were quantified using Human IL-29/IL-28B (IFN-lambda 1/3) and Mouse IL-28A/B (IFN-lambda 2/3) DuoSet ELISA kits (R&D Systems, Minneapolis, MN USA), respectively. The working range of the assays was 62.5-4000 pg/ml.

Viral titer determination
Viral titers were determined using a plaque assay as described in Additional file 1.

Western blot analysis
IAV nucleoprotein (NP) levels and phosphorylation of IFN regulatory factor (IRF)3 and IRF7 were assessed using western blotting as described in Additional file 1.
Murine infection model
Experiments with 7-week-old male C57BL/6J (B6) mice (OrientalBio, Seoul, Korea) were carried out according to guidelines approved by the Institutional Review Board of the Seoul National University College of Medicine (IACUC #2016-0093). Microbiome depletion, S. epidermidis and IAV infection, nasal lavage (NAL) and bronchoalveolar lavage (BAL) sample collection, and lung tissue harvesting are described in Additional file 1.

Histological analysis
Fixing, hematoxylin/eosin staining, and histological analysis of the mouse lung tissues were carried out as described [18]. Peribronchiolar inflammation was scored using an 8-point scale. Lung sections from at least five mice, with at least six areas from each section, were examined. The five best sections were used for evaluation.

Statistical analyses
The in vitro studies were performed at least in four independent cultures of NHNE cells from each donor. Differences between treatment groups were evaluated by analysis of variance (ANOVA) with a post hoc test. Between-group differences in studies in vivo, performed using five mice, were determined using Mann-Whitney U tests. Statistical analyses were performed using Graph-Pad Prism (v.5; GraphPad Software, La Jolla, CA, USA). A p value < 0.05 was considered significant.

Results
Characterization of bacterial communities in healthy nasal mucus
The local microbiome of the middle turbinate mucus of healthy human subjects (N = 20) was analyzed by cultured bacterial colony and 16S rRNA gene sequencing. Based on at least 97% sequence identity, 46 bacterial species were detected in the middle turbinate mucus. S. epidermidis, Corynebacterium pseudodiphtheriticum, Enterobacter aerogenes, Citrobacter koseri, Klebsiella pneumoniae, Corynebacterium accolens, Staphylococcus aureus, and Apteryx australis were among the most commonly identified species. S. epidermidis demonstrated the highest abundance, accounting for 35.53% of the mapped sequences (Fig. 1a). The abundance of nasal commensal S epidermidis was different in each patient, and the highest distribution reached 54.2%. The lowest abundance of S. epidermidis was 12.3% in the nasal commensal of healthy nasal mucus (Fig. 1b). To assess the role of this commensal organism in human nasal mucus, S. epidermidis strains isolated from four subjects (N1, N2, N3, and N4) were analyzed.

S. epidermidis pretreatment suppresses IAV replication in the nasal epithelium
To analyze the effects of S. epidermidis pretreatment on the susceptibility of the nasal epithelium to IAV infection, NHNE cells from five healthy subjects were infected with IAV at a multiplicity of infection (MOI) of 1. Subsequently, IAV levels were assessed in the supernatants and cell lysates harvested at different time points post-infection. Real-time PCR revealed that IAV PA mRNA levels increased significantly starting at 1 day post-infection (dpi; mean IAV mRNA: 2.1 × 10^5, 1 dpi; 2.4 × 10^5, 2 dpi; 8.1 × 10^5, 3 dpi; Fig. 1c). Plaque assays also found increased IAV titers starting at 1 dpi and a peak titer of 5.8 × 10^6 plaque-forming units (PFU)/ml was observed at 3 dpi (Fig. 1d). Western blot analysis similarly revealed that IAV NP levels significantly increased by 1 dpi and continued to increase through to 3 dpi (Fig. 1e). These findings demonstrated the significant susceptibility of the nasal epithelium to IAV infection from 1 dpi.

To examine the effect of S. epidermidis on the antiviral immune response, NHNE cells were treated with S. epidermidis N1 (MOI = 0.25) at 8 h before inoculation of IAV (MOI = 1). The increase in IAV PA mRNA level (4.2 × 10^4) in IAV-infected NHNE cells at 1 dpi was significantly attenuated by S. epidermidis (1.3 × 10^5) (Fig. 1f). Viral titers were also significantly lower in the supernatants of NHNE cells co-infected with IAV and S. epidermidis than in those of cells infected with IAV alone (Fig. 1g). Similarly, S. epidermidis exposure also decreased IAV NP levels in IAV-infected NHNE cells (Fig. 1h). Interestingly, no reduction in viral load was observed in IAV-infected NHNE cells which were inoculated with boiled S. epidermidis (Fig. 1i). S. epidermidis strains isolated from the nasal mucus of other healthy subjects (N2, N3, and N4) also reduced IAV viral titer and protein levels (Fig. 1j, k). However, viral titers and NP levels were not reduced in NHNE cells infected with a non-pathogenic laboratory S. epidermidis ATCC 12228 strain [19] before IAV. These findings suggested that commensal S. epidermidis native to the human nasal passages can specifically suppress IAV replication in nasal epithelium.

S. epidermidis preferentially induces IFN-λ in NHNE cells
To assess the mechanisms of the S. epidermidis-dependent antiviral immune response in the nasal epithelium, we measured the expression of IFN genes in S. epidermidis-exposed NHNE cells. S. epidermidis isolated from healthy individuals (N1, N2, N3, and N4) significantly elevated the levels of IFNL1 and IFNL2/3 mRNA in NHNE cells starting at 8 h after treatment, with maximum levels observed 24 h after infection (IFNL1 6.4 × 10^5, IFNL2/3 1.1 × 10^4, Fig. 2a). S. epidermidis similarly
Fig. 1 (See legend on next page.)
induced the secretion of IFN-λ (1 dpi, 586.4 pg/ml, Fig. 2b) but did not increase the expression of genes encoding IFN-α, IFN-β, and IFN-γ.

When NHNE cells were inoculated with S. epidermidis prior to IAV, S. epidermidis induced IFN-λ more significantly in IAV-infected NHNE cells. NHNE cells treated with nasal commensal S. epidermidis 8 h before IAV infection demonstrated higher levels of gene expression (IFNL1 4.2 × 10^4, IFNL2/3 4.8 × 10^5) and secretion of IFN-λ (1412.4 pg/ml) than cells infected with IAV alone (IFNL1 5.6 × 10^4, IFNL2/3 2.7 × 10^5, 511.5 pg/ml) (Fig. 2c, d). However, pretreatment of NHNE cells with the non-pathogenic laboratory S. epidermidis ATCC 12228 strain before IAV infection did not result in a similar induction. Considering the more significant induction of IFN-λ observed, we subsequently assessed the effect of S. epidermidis on mRNA levels of the IFN-stimulated genes (ISGs) encoding CXCL10, IFIT1, Mx1, and OAS1, which are required for the innate immune response against IAV. Transcript levels of all four genes were significantly elevated in nasal commensal S. epidermidis-treated NHNE cells before IAV infection (CXCL10 1.9 × 10^4, IFIT1 1.7 × 10^4, Mx1 7.4 × 10^3, OAS1 7.1 × 10^3) (Fig. 2e) relative to untreated cells and those infected with IAV alone. In contrast, no induction was observed in cells pretreated with S. epidermidis ATCC 12228 prior to IAV infection.

As a next step, NHNE cells were transfected with short hairpin (sh)RNA of IL28R, which is a region of the IFN-λ receptor, to cause a functional loss of the IFN-λ-related signaling pathway. Interestingly, the significant decrease of IAV PA mRNA level (2.1 × 10^5) and viral titer (1.1 × 10^6 pfu/ml) in S. epidermidis-treated NHNE cells before IAV infection was not observed in NHNE cells with transfection of IL28R shRNA (Fig. 2f, g). These data suggested that nasal commensal S. epidermidis induces IFN-λ production and secretion and facilitates IFN-related innate immune responses against IAV.

**S. epidermidis promotes IAV clearance independently of pattern recognition receptors**

To further investigate the mechanisms of significant IFN-λ induction by nasal mucus-derived S. epidermidis, we assessed mRNA levels of genes encoding pattern recognition receptors in NHNE cells infected with IAV in the absence or presence of S. epidermidis pretreatment. Transcripts encoding TLR2, TLR3, RIG-I, and MDA5 were not more elevated in NHNE cells treated with S. epidermidis and IAV relative to those in cells infected with IAV alone (Additional file 1: Figure S1). The transcription levels of TLR2 mRNA was higher in S. epidermidis-inoculated NHNE cells than TLR3, RIG-I, and MDA5 at 1 dpi (Fig. 3a). Thus, we next assessed the impact of TLR2 on S. epidermidis-dependent modulation of IAV infection by transfecting NHNE cells with shRNA to suppress the expression of TLR2 mRNA. Suppression of TLR2 expression prior to IAV infection did not alter S. epidermidis-dependent effects on IAV PFU levels. Viral titers were reduced in NHNE cells treated with S. epidermidis before IAV infection (1.3 × 10^5 pfu/ml) relative to those in cells infected with IAV alone in a manner independent of TLR2 shRNA (4.3 × 10^5 pfu/ml) (Fig. 3b).

To assess the S. epidermidis-related modulation of IFN-λ expression at the transcription level, we investigated the phosphorylation states of IFN regulatory factor (IRF) 3 and IRF7, which are required for transcription of IFN-λ in respiratory epithelium. Although total levels of IRF3 and IRF7 remained unchanged, those of the respective phosphorylated proteins were elevated in IAV-infected NHNE cells at 1 dpi relative to non-treated cells. Interestingly, levels of phosphorylated IRF7 were further increased in NHNE cells treated with S. epidermidis before IAV infection relative to those in cells infected with IAV alone (Fig. 3c). Together, these findings indicated that nasal commensal S. epidermidis can promote phosphorylation of IRF7 to induce IFN-λ...
expression and can suppress IAV replication independently of TLR2.

**S. epidermidis** abundance and IFN-λ expression are positively correlated in human nasal mucosa

Considering the in vitro effect of nasal commensal **S. epidermidis** strains on IFN expression and IAV infection, we next investigated the relationship between **S. epidermidis** abundance and IFN-λ mRNA levels. Nasal mucus and middle turbinate mucosa of 17 healthy subjects were collected and assessed for the number of **S. epidermidis** colony-forming units (CFU) and IFN-λ1 and IFN-λ2/3 mRNA levels were measured using turbinate mucosa. Nasal commensal **S. epidermidis** CFUs positively correlated with mRNA levels of IFN-λ1 \( (r = 0.566, p = 0.018) \) and IFN-λ2/3 \( (r = 0.446, p = 0.049) \) in the nasal mucosa of the same subjects (Fig. 3d, e). These data indicated that the levels of **S. epidermidis** in the nasal mucus proportionally affect the transient expression of IFN-λ in nasal mucosa.

**S. epidermidis** pretreatment prevents IAV lung infection in vivo through suppression of IAV replication in the nasal mucosa.

Considering our observations, we next assessed the **S. epidermidis** anti-IAV protective properties in vivo using a murine model of infection. The nasal cavities of B6...
mice (N = 4) were inoculated with human nasal mucus-derived S. epidermidis at 2 days (day 5) following nasal microbiota-depletion (days 1, 2, and 3) using 30 μl of an antibiotic cocktail (vancomycin, neomycin, ampicillin, and metronidazole). Then, S. epidermidis-inoculated B6 mice were infected with IAV (213 pfu/30 μl) at 2 days after S. epidermidis inoculation (day 7) (Fig. 4a).

As gross determinants of virus-induced morbidity, the body weights and survival rates of the infected B6 mice were monitored for 7 days. IAV-infected mice exhibited a significant decrease in mean body weight with an 80% survival rate until 7 dpi. Interestingly, B6 mice that were administered human nasal mucus-derived S. epidermidis before IAV infection did not exhibit a significant weight loss until 7 dpi and the mean body weight of these mice exceeded 20 g until 7 dpi resulting in 100% survival of mice after IAV infection (Fig. 4b).

Compared to mice infected with IAV alone (2.8 × 10^5), those infected with IAV following S. epidermidis inoculation showed lower IAV PA mRNA levels (4.2 × 10^4) in the lung tissue (Fig. 4c) and the S. epidermidis/IAV exposure also resulted in attenuated pathologic findings in the lung, with significantly lower histologic scores (Fig. 4d). However, significant lung pathologic findings were obtained from B6 mice that were administered the non-pathogenic laboratory S. epidermidis ATCC 12228 strain before IAV infection compared to the mice that were inoculated with human nasal mucus-derived S. epidermidis (Fig. 4e).

We next assessed the distribution of bacteria in S. epidermidis-inoculated mice by comparing the CFUs in the NAL and BAL samples. Whereas substantial numbers of S. epidermidis CFUs were observed in the NAL samples, the levels of S. epidermidis cells in the BAL samples were under the detection limit (Fig. 4f). We also asked whether these differences in S. epidermidis distribution translate into specific patterns of IFN-λ expression in the mice. IAV infection alone resulted in elevated IFNL2/3 gene expression in the nasal mucosa and lung tissue, as well as in increased secreted IFN-λ protein levels in the nasal mucosa from middle turbinate of healthy volunteers (n = 17), as measured by real-time PCR, were correlated with the colony-forming units (CFUs) of S. epidermidis isolated from the mucus of the middle turbinate collected from the same subjects. The correlation was determined by Spearman’s correlation analysis.
Fig. 4 (See legend on next page.)
animals accompanied with completely lower viral replication in vivo lung (Fig. 4g, h). Together, these findings demonstrated that the nasal nasal commensal S. epidermidis can boost the IFN-λ-dependent innate immune response in mouse nasal mucosa, thereby suppressing IAV replication at the level of the nose and preventing acute IAV lung infection.

Discussion

Our study revealed that S. epidermidis is the most abundant microbiome that colonizes healthy human nasal mucus and the distribution of S. epidermidis might be significantly associated with IFN-λ-dependent innate immune responses in the nasal mucosa. Our findings also imply that the intranasal administration of S. epidermidis is a potential strategy for the prevention of respiratory viral infections by controlling viral replication at the level of the nasal mucosa. This study presents novel evidence of the role played by the healthy human nasal microbiome in the defense against IAV replication in the nasal mucosa.

Respiratory mucosa is the first target organ for environmental pathogens, including respiratory viruses. Recent work has highlighted the critical role of respiratory mucosa as a barrier for restricting the invasion of the host by multiple pathogens [10, 20–22]. The compositional and predicted functional differences in the respiratory microbiome resulting from environmental stimuli have been gaining increasing interest and the importance of the respiratory microbiome, especially with respect to immune protection, has been greatly recognized [23–28]. Therefore, understanding the composition and potential adverse changes in the respiratory mucosal microbiome is essential for developing new approaches for the prevention and treatment of respiratory infections. The nasal mucosa is also a key player in immunological defense to protect the respiratory tract and is responsible for filtration of inhaled pathogens from direct exposure to pressurized airflow [21, 22]. There is also growing evidence that a microbiome community resides in the nasal nucus, which is secreted by epithelial cells, and covers the whole surface of the mucosa, and we found that S. epidermidis is the most abundant commensal organism in the human nasal mucus, accounting for ~ 35% of the identified bacterial species. Human respiratory viruses first encounter host defense mechanisms in the upper or lower respiratory epithelium [29–34]. Host protection against viral infections can be conferred by innate resistance, with a specialized innate immune system of nasal epithelium capable of combating invasion by respiratory viruses [10]. Thus, we focused on the contribution of S. epidermidis to antiviral innate immune defense mechanisms of the nasal mucosa.

Antiviral innate immunity in the respiratory tract is mediated by an increase in IFN secretion [35–41]. The role of type 1 IFNs in antiviral innate immune responses and the activation of the adaptive immune system have been well documented [42–44]. Increasing evidence shows that IFN-λ is also critical for antiviral innate immunity in the respiratory tract, with disrupted IFN-λ-related innate immunity increasing susceptibility to respiratory viral infections [45–48]. Some studies have reported that IFN-λ is the primary cytokine that mediates the antiviral response against rhinovirus and influenza virus in the lungs [46, 49–51]. We have also reported that IFN-λ represents the predominant IFN type induced by IAV and contributes to the first-line defense against viral infections in human nasal epithelial cells [10]. We have concentrated on verifying the immune mediators for IFN-λ in the nasal mucosa and propose that IFN-λ can be regulated by the nasal microbiome, with S. epidermidis as the most abundant commensal organism. Here, we found that nasal commensal S. epidermidis showed potent antiviral activity in nasal epithelium and all ensuing antiviral responses from S. epidermidis are dependent on the production of IFN-λ without affecting IFN-α, IFN-β, and IFN-γ expression because responses are lost in nasal epithelial cells lacking specific receptors for IFN-λ, as shown in Fig. 2f and g. This hypothesis is underscored by the positive correlation between IFN-λ mRNA levels of nasal mucosa and S. epidermidis colony numbers in human nasal mucus.
Thus, a higher abundance of *S. epidermidis* in the nasal mucus of healthy individuals results in higher baseline IFN-λ levels in the absence of a viral infection.

We furthermore demonstrated that the nasal commensal *S. epidermidis* confers protection against IAV infection. Relative to infection with IAV alone, inoculation of *S. epidermidis* before IAV infection reduced the viral burden of NHNE cells, while concomitantly inducing IFN-λ and ISG expression. Previous research has shown that *S. epidermidis* directly binds influenza virus, with the extracellular matrix-binding protein Embp identified as a major contributor to the anti-influenza effect of *S. epidermidis* ATCC 12228 [19]. However, in our in vitro system using full differentiated human nasal epithelium, the laboratory *S. epidermidis* ATCC 12228 strain was not capable of reducing the viral burden of IAV-infected NHNE cells or of inducing IFN-λ production. We speculate that the nasal commensal *S. epidermidis* possess specific characteristics, distinct from those of non-pathogenic laboratory *S. epidermidis* ATCC 12228 or of respiratory tract pathogens, that allow it to boost baseline immune mechanisms through IFN-λ. These findings suggest that commensal *S. epidermidis* specifically from human nasal mucus shows distinctive antiviral immune responses against IAV through induction of IFN-λ from at least 8 h after inoculation.

In addition to showing in vitro activity in NHNE cells, nasal mucus-derived *S. epidermidis* also suppressed IAV-caused lung infection in vivo. Inoculation of mice with human commensal *S. epidermidis* strains prior to IAV infection increased the expression of IFN-λ in the mouse nasal mucosa and prevented IAV-induced lung tissue damage. We hypothesize that the mice that received the human commensal bacteria prior to IAV infection had limited IAV replication in their nasal mucosa, thereby preventing acute lung infection. We did not observe direct binding between human commensal *S. epidermidis* and IAV in vitro or in vivo.

The current findings indicate that nasal commensal *S. epidermidis* could be detected by TLR2 in the nasal epithelium but *S. epidermidis* induced IFN-λ through direct signal transduction to transcription factors regardless of recognition by TLR2. Both IRF3 and IRF7 have been characterized as transcription factors for IFNs and IFN-λ induction depends on direct signal transduction through the phosphorylation of IRF3 and IRF7 [48, 52]. While IRF3 is generally regarded as the transcription factor required for the initiation of IFN transcription, IRF3 deficiency has little impact on IFN expression [52]. In contrast, lack of IRF7 reduced IFN production significantly in airway epithelium [52]. Our data explain how nasal commensal *S. epidermidis* could promote phosphorylation of IRF7 rather than IRF3 and finally induce IFN-λ-related immune responses in nasal epithelium.

We did not show the definite paradigm for *S. epidermidis*-enhanced phosphorylation of IRF7 in nasal epithelium. We just speculate that *S. epidermidis*-secreted molecules interact with IRF7 and are primarily responsible for the phosphorylation of IRF7 for the more potent induction of IFN-related antiviral immune responses in airway epithelium.

As shown in Fig. 1i and j, it is of interest that the non-pathogenic *S. epidermidis* strain (ATCC #12228) failed to induce protective effects against IAV infection. This supports the notion that the *S. epidermidis* strains recovered from the human nasal cavity might have acquired novel genetic features during the long-term symbiosis in the human nasal mucosa. The comparative genomic analysis will provide insights into the genetic determinants that help us understand mechanisms by which our innate immunity is activated in response to the symbiotic interaction with a commensal microbe.

### Conclusion

Our study provides a greater understanding of how the nasal microbiome enhances IFN-dependent innate immune responses to protect the respiratory tract against influenza viral infection. We showed that the abundant human nasal commensal organism *S. epidermidis* enhances resistance against IAV infection in human nasal epithelium through IRF7-dependent IFN-λ amplification and prevents IAV lung infection through the suppression of IAV replication at the level of the nasal mucosa. Thus, intranasal delivery of the human nasal commensal *S. epidermidis* represents a potential therapeutic approach for preventing and treating respiratory viral infections via induction of IFN-λ-related innate immune responses.

### Additional files

**Additional file 1:** Supplementary material and methods with supplementary figures. (DOC 1276 kb)

**Additional file 2:** Movie S1. Mucus and/or nasal mucosa from the middle turbinates of the human subjects. (AVI 4230 kb)

### Abbreviations

B6: C57BL/6; BAL: Bronchoalveolar lavage; CFU: Colony-forming unit; DPI: Day post-infection; IAV: Influenza A virus; IFN: Interferon; IRF: Interferon regulatory factor; ISG: Interferon-stimulated genes; MDCK: Madin-Darby canine kidney; MOI: Multiplicity of infection; NAL: Nasal lavage; NHNE: Normal human nasal epithelium; NP: Nucleoprotein; TLR: Toll-like receptor

### Authors’ contributions

HJK and AJ conceived the study and designed the experiments. SA, AJ, YJJ, and HJK carried out the study including sample collection and sample preparation. KML and SSY performed additional work, design, and data analysis. HJK, SSY, and JYC drafted the manuscript. All authors read and approved the final manuscript.

### Funding

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of
Education (2016R1D1A1B01014116 to H.J.K) and (2017M3A9F3A041233 to S.S.Y). This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI18C1337 to H.J.K), and the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2014M3A9D5A01073865 to J.Y.C).

Availability of data and materials
Not applicable

Ethics approval and consent to participate
Participation was voluntary, with written informed consent obtained from all subjects. The Institutional Review Board of the Seoul National University College of Medicine approved the protocol for this study (IRB #C2012248 [943]). In vivo experiments with C57BL/6J mice were carried out according to guidelines approved by the Institutional Review Board of the Seoul National University College of Medicine (IACUC #2016-0093).

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Republic of Korea. 2Seoul National University Hospital, Seoul, Republic of Korea. 3Department of Microbiology and Immunology, Brain Korea 21 PLUS Project for Medical Sciences, Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. 4Department of Otorhinolaryngology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. 5Department of Otorhinolaryngology, Gyeongsang National University Hospital, Jinju, Republic of Korea.

Received: 4 July 2018 Accepted: 8 May 2019
Published online: 30 May 2019

References
1. Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in detente. Science. 2006;312:879–82.
2. Cheon H, Holvel-Bates EG, Schoggins JW, Forster S, Hertzog P, Inama N, Rice CM, Jackson MW, Junk DJ, Stark GR. IFNBeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 2013;32:2751–63.
3. Kim HJ, Kim CH, Ryu JH, Kim MJ, Park CY, Lee JM, Holtzman MJ, Yoon JH. Reactive oxygen species induce antiviral innate immune response through IFN-lambda regulation in human nasal epithelial cells. Am J Respir Cell Mol Biol. 2013;49:855–65.
4. Sheppard K, Kindsvogel W, Xu W, Henderson K, Schlutemeyer S, Whitmore TE, Kuehnter R, Gargioui U, Binks C, Roraback J, Ostrander C, Dong D, Shin J, Pressnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant JF, Tackett M, Kirvan W, McKnight G, Gregg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:633–8.
5. Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manoudaki M, Thanos D, Doyle SE, Kotecko SV, Thnopoulos K, Andreako E. Interferon-α mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity. 2017;46:875–90.
6. Sheahan T, Inama N, Marukian S, Donner M, Liu P, Plass A, Rice CM. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe. 2014;15:190–202.
7. Nice TJ, Baldrige MT, McCune BT, Norman JM, Lazear HM, Artymov M, Diamond MS, Virgin HW. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015;347:269–73.
8. Ertuk-Hasdemir D, Kasper DL. Resident commensals shaping immunity. Curr Opin Immunol. 2013;25:450–5.
Johnston SL, Edwards MR. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog. 2010;6:e1001178.

33. Allen IC, Scull MA, Moore CB, Holl Ek, McElvania-Tekippe E, Taxman DJ, Guthrie EH, Pickles RJ, Ting JP. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity. 2009;30:556–65.

34. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14:315–28.

35. Pang IK, Iwasaki A. Inflammasomes as mediators of immunity against influenza virus. Trends Immunol. 2011;32:34–41.

36. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, García-Sastre A. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci. 2010;107:11531–6.

37. Perrone LA, Plovednik J, García-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 2008;4:e1000115.

38. Höglker N, Wolff T, Pieschka S, Plog S, Gruber AD, Kallinke U, Walmrath HD, Bodner J, Gatterlöhner S, Leve-Schlosser M, Sieger W, Lohmeyer J, Herold S. Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog. 2013;9:e1003188.

39. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8–32.

40. Kohlmeier JE, Cookenham T, Roberts AD, Millem SCR, Woodland DL. Type I interferons regulate cytolytic activity of memory CD8+ T cells in the lung airways during respiratory virus challenge. Immunity. 2010;33:96–105.

41. Cakebread JA, Xu Y, Grange C, Kehagia V, Howarth PH, Holgate ST, Davies DE. Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol. 2011;127:1148–54.

42. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell. 1998;1:507–18.

43. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem. 2007;282:7576–81.

44. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Jalkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol. 2007;179:3434–42.

45. Kotenko SV. IFN-λs. Curr Opin Immunol. 2011;23:583–90.

46. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebedze T, Malla P, Stanicu LA, Parker HL, Slater I, Lewis-Artes A, Ken OM, Holgate ST, Davies DE, Kotenko SV, Papa A, Johnston SL. Role of deficient type II interferon-lambda production in asthma exacerbations. Nat Med. 2006;12:1023–6.

47. Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, Sheehan KC, Schreiber RD, Oldstone MB. Blockade of interferon beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe. 2015;17:653–61.

48. Zhou Z, Hammig O, Anik N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol. 2007;81:7749–58.

49. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flahos E, Schindler C, Grieves JL, Durbin RK, Kotenko SV, Durbin JE. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol. 2010;84:11515–22.

50. Mordstein M, Kochs G, Dumonier L, Renault IC, Paludan SR, Kucher K, Staeheil P. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hematopoietic viruses. PLoS Pathog. 2008;4:e1000151.

51. Kim S, Kim MJ, Kim CH, Kang JW, Shin HK, Kim DT, Won TB, Han DH, Rhee CS, Yoon JH, Kim HJ. The superiority of IFN-lambda as a therapeutic candidate to control acute viral infection. Am J Respir Cell Mol Biol. 2017;56:202–12.

52. Crotta S, Davidson S, Mahlaokos T, Desmet CJ, Buckwalter MR, Albert ML, Staheili P, Wack A. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog. 2013;9:e1003773.